Cancer clinical trials in the region Occitanie

385 currently recruiting clinical trials
Region Occitanie
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06888921 #2025-521125-33-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy
8 recruiting sites
Compugen Ltd
Phase 1 / Phase 2 Lymphoma #NCT05607420 #2022-501607-27-00
Partie escalade de dose
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma Primary mediastinal lymphoma Mantel cell lymphoma Follicular lymphoma Marginal zone lymphoma MALT lymphoma Indolent transformed lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive Car-T
4 recruiting sites
Cellectis SA
Phase 1 / Phase 2 Lymphoma #NCT05607420 #2022-501607-27-00
Partie extension de dose
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma Follicular lymphoma Indolent transformed lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive Car-T
4 recruiting sites
Cellectis SA
Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT06923761 #2023-504845-30-00
Module 2 Partie D cancer colorectal pMMR/MSS
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2 Lung cancer #NCT06669117 #2024-512760-64-00
Parties 2a et 2b
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06669117 #2024-512760-64-00
Partie 1 (Escalade de dose)
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2 Kidney cancer #NCT07049926 #2024-516437-12-00
Required histologic types
Clear cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Immunotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Merck Sharp & Dohme LLC
Phase 1 / Phase 2 Lung cancer #NCT05118789
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ROS-1
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2 Lung cancer #NCT05118789
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ROS-1
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT05706129 #2023-504254-35-00
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Debiopharm International SA